文献速递心律失常冠心病

房颤急性缺血性卒中后早期与延迟启动NOAC的TIMING随机研究

Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.
PubMed 文献 · Circulation · 2022-09-06

TIMING为基于注册的随机、非劣效、开放标签、盲法终点研究,在34个卒中单元纳入888例房颤急性缺血性卒中患者,随机分为早期(≤4天)或延迟(5-10天)启动NOAC。90天主要复合终点(复发性缺血性卒中、症状性颅内出血或全因死亡)早期组6.89%、延迟组8.68%,绝对风险差-1.79%(95%CI -5.31%至1.74%),非劣效P=0.004,两组均无症状性颅内出血,提示早期启动NOAC非劣于延迟启动且安全。

要点

  • 房颤急性缺血性卒中后早期(≤4天)启动NOAC在90天主要复合终点上非劣于延迟(5-10天)启动。
  • 早期组与延迟组均未发生症状性颅内出血,早期启动安全性可接受。
  • 早期组缺血性卒中(3.11% vs 4.57%)和全因死亡(4.67% vs 5.71%)数值上更低,但置信区间宽。

核心结论

  • 房颤急性缺血性卒中后早期(≤4天)启动NOAC非劣于延迟(5-10天)启动,90天主要复合终点绝对风险差-1.79%(95%CI -5.31%至1.74%),非劣效P=0.004。

研究设计与样本

  • TIMING为基于注册的随机、非劣效、开放标签、盲法终点研究,在34个卒中单元利用瑞典卒中注册进行入组和随访。
  • 共随机888例患者至早期组(n=450)或延迟组(n=438),90天随访无失访;平均年龄78.3岁(SD 9.9),46.2%为女性。

主要发现

  • 主要复合终点(复发性缺血性卒中、症状性颅内出血或全因死亡)早期组31例(6.89%),延迟组38例(8.68%)。
  • 缺血性卒中率早期组3.11%、延迟组4.57%,风险差-1.46%(95%CI -3.98%至1.07%)。
  • 全因死亡率早期组4.67%、延迟组5.71%,风险差-1.04%(95%CI -3.96%至1.88%)。
  • 两组均无患者发生症状性颅内出血。

关键数值与推荐

  • 预设非劣效界值为3%。
  • 主要终点非劣效P=0.004。

临床怎么用

  • 对适合NOAC治疗的房颤急性缺血性卒中患者,可考虑早期(≤4天)启动NOAC用于急性期二级预防。
  • 早期启动未增加症状性颅内出血,安全性支持其临床应用。

局限性

  • 开放标签设计,尽管终点采用盲法评估。
  • NOAC选择由研究者自行决定,未统一药物种类或剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are no evidence-based recommendations on the optimal time point to initiate non-vitamin K antagonist oral anticoagulants (NOACs) after acute ischemic stroke in patients with atrial fibrillation. We aimed to investigate the efficacy and safety of early versus delayed initiation of NOAC in these patients. METHODS: TIMING (Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation) was a registry-based, randomized, noninferiority, open-label, blinded end-point study at 34 stroke units using the Swedish Stroke Register for enrollment and follow-up. Within 72 hours from stroke onset, patients were randomized to early (≤4 days) or delayed (5-10 days) NOAC initiation, with choice of NOAC at the investigators' discretion. The primary outcome was the composite of recurrent ischemic stroke, symptomatic intracerebral hemorrhage, or all-cause mortality at 90 days. The prespecified noninferiority margin was 3%. Secondary outcomes included the individual components of the primary outcome. RESULTS: Between April 2, 2017, and December 30, 2020, 888 patients were randomized to either early (n=450) or delayed (n=438) initiation of NOAC. No patient was lost to 90-day follow-up. Mean age was 78.3 years (SD, 9.9 years); 46.2% were women; 49.1% had previously known atrial fibrillation; and 17.5% prior stroke. The primary outcome occurred in 31 patients (6.89%) assigned to early initiation and in 38 patients (8.68%) assigned to delayed NOAC initiation (absolute risk difference, -1.79% [95% CI, -5.31% to 1.74%]; Pnoninferiority=0.004). Ischemic stroke rates were 3.11% and 4.57% (risk difference, -1.46% [95% CI, -3.98% to 1.07%]) and all-cause mortality rates were 4.67% and 5.71% (risk difference, -1.04% [95% CI, -3.96% to 1.88%]) in the early and delayed groups, respectively. No patient in either group experienced symptomatic intracerebral hemorrhage. CONCLUSIONS: Early initiation was noninferior to delayed start of NOAC after acute ischemic stroke in patients with atrial fibrillation. Numerically lower rates of ischemic stroke and death and the absence of symptomatic intracerebral hemorrhages implied that the early start of NOAC was safe and should be considered for acute secondary stroke prevention in patients eligible for NOAC treatment. REGISTRATION: URL: http://www. CLINICALTRIALS: gov; Unique identifier: NCT02961348.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Oldgren, Åsberg, Hijazi, et al. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation. 2022. PMID: 36065821. doi:10.1161/CIRCULATIONAHA.122.060666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。